Fox Chase Cancer Center | Strategic Alliance Partners

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Fox Chase Cancer Center was recognized by the ECOG-ACRIN Cancer Research Group for outstanding achievement in accrual, scientific contribution, and more.

Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference for her work detailing the mychoice digital health tool.

Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms.

Edna “Eti” Cukierman, PhD, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Alexander Kutikov, MD, FACS, chair of the Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, will receive the Andrew C. Novick Award from the Kidney Cancer Association.

Rebecca Shulman, MD, assistant professor in the Department of Radiation Oncology at Fox Chase Cancer Center, was recently recognized with the Robert A. Winn Diversity in Clinical Trials Career Development Award.

As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells.

Igor Astsaturov, MD, PhD, has been appointed inaugural holder of the Paul F. Engstrom Professorship in Oncology.

Temple Health was recently recognized with the American College of Gastroenterology’s Service Award for Colorectal Cancer Outreach, Prevention & Year-Round Excellence for its coordinated health campaign against colon cancer.

Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.

In a recent study, researchers at Fox Chase Cancer Center demonstrated how amplification and rearrangement of a gene associated with leukemia known as MLL is directly controlled by epigenetic factors, providing needed insights into a new therapeutic opportunity.

Researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University will serve as two of the principal investigators on the Asian American Community Cohort and Equity Study, which is part of a new seven-year epidemiological cohort study of Asian Americans, Native Hawaiians, and Pacific Islanders.

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Melissa Culligan, RN, MS, PhD candidate, director of Thoracic Surgery Research at Temple Health, was recently honored with the International Association for the Study of Lung Cancer’s Lectureship Award for Nurses and Allied Health Professionals.

Fox Chase Cancer Center is pleased to announce the hiring of Sara Small, MD, PhD, as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.

Anna Liza Rodriguez, MSN, MHA, RN, OCN, NEA-BC, Chief Nursing Officer at Fox Chase Cancer Center, is a finalist in the Nursing Administration – Executive/CNO category for the 2023 Nightingale Awards of Pennsylvania, which recognize nursing excellence in the state.

Fox Chase Cancer Center and Temple Health are pleased to announce the hiring of Randall A. Lee, MD, as an Assistant Professor in the Department of Urology and a member of the Fox Chase-Temple Urologic Institute.

Anjali Albanese, MSW, LSW, OSW-C, a licensed social worker at Fox Chase Cancer Center, will receive the Compassionate Care Award from the Sarcoma Foundation of America during the Stand Up to Sarcoma Gala on September 19 in New York.

A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure and stability, work that has implications for cancer, Alzheimer’s, and other degenerative diseases and continues the Fox Chase legacy of basic research.

Fox Chase Cancer Center is pleased to announce the hiring of Christopher G. Cann, MD, as an assistant professor in the Department of Hematology/Oncology with a focus on gastrointestinal cancers.

Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Lucia Borriello, PhD, an assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University and a member of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, has been awarded a three-year $450,000 research grant from Susan G. Komen.

Fox Chase Cancer Center is pleased to announce the hiring of Peter A. McCue, MD, as a Professor in the Department of Pathology.